Shares of Agenus Inc. bounced 12.7 percent Monday on Phase II results published in Neuro-Oncology showing more than 90 percent of recurrent glioblastoma multiforme (GBM) patients treated with Prophage Series G-200 were alive at six months after surgery, and 30 percent survived 12 months, with median overall survival of 11 months. That is an improvement over typical median survival of three to nine months.